Leap Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 41.86 million compared to USD 10.38 million a year ago. Basic loss per share from continuing operations was USD 3.2 compared to USD 0.9 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.93 USD | -3.50% |
|
+3.21% | -53.44% |
Jul. 01 | Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell 3000E Index | CI |
Jul. 01 | Leap Therapeutics, Inc.(NasdaqCM:LPTX) added to Russell Microcap Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.44% | 73.85M | |
+18.43% | 124B | |
+19.81% | 114B | |
-23.74% | 19.42B | |
-18.10% | 16.2B | |
-19.97% | 15.31B | |
-49.33% | 14.19B | |
+57.08% | 14.32B | |
+7.95% | 14.31B | |
+126.04% | 11.29B |
- Stock Market
- Equities
- LPTX Stock
- News Leap Therapeutics, Inc.
- Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023